A Phase I/II Trial of Zidovudine, Interferon-α, and Granulocyte-Macrophage Colony-Stimulating Factor in the Treatment of Human Immunodeficiency Virus Type 1 Infection

Twety-four patients infected with human immunodeficiency virus type 1 (HIV-1) who had CD4 + counts of 0.2-0.5×10 9 cells/l received granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with zidovudine plus escalating doses of daily subcutaneous interferon-α